James (Jim) Fendrick’s Post

PolTREG has identified a promising efficacy biomarker that may facilitate monitoring the health of Type-1 diabetes patients treated with T-regulatory cells. This is described in a study, published in the prestigious magazine International Immunopharmacology. “This peer-reviewed scientific publication adds to our growing excitement about the potential of polyclonal Treg therapies,” Chief Executive Officer Piotr Trzonkowski said in a press release about the publication. The article, which Prof Trzonkowski co-authored, presented data suggesting that PD-1+ T-cells are a dependable biomarker for efficacy in pediatric early-onset Type-1 diabetes patients, which had received Treg therapy in combination with rituximab. PolTREG has treated more than 100 patients with cell therapies at its facility over the past 17 years. This has given the company a wealth of data, and unrivalled experience with how Type-1 Diabetes and other autoimmune diseases respond to treatment. For a link to the press release, click here: https://lnkd.in/dat2hSgT To read the article, click here: https://lnkd.in/dPF-Yknf #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #investing #diabetes

Mesenchymal stromal/stem cells (MSCs) are widely utilized in #celltherapy because of their robust immunomodulatory and regenerative properties. Their paracrine activity is one of the most important features that contribute to their efficacy. Recently, it has been demonstrated that the production of various factors via #extracellularvesicles, especially #exosomes, governs the principal efficacy of MSCs after infusion in experimental models. Compared to #MSCs themselves, MSC-derived exosomes (MSC-Exos) have provided significant advantages by efficiently decreasing unfavorable adverse effects, such as infusion-related toxicities. MSC-Exos is becoming a promising cell-free therapeutic tool and an increasing number of clinical studies started to assess the therapeutic effect of MSC-Exos in different diseases. MSC-Exos engage in intercellular communication, serving as carriers to deliver proteins, mRNA, and microRNAs into targeted cells. More than 304 #proteins and 150 #microRNAs have been found in MSC-Exos in addition to other #bioactive molecules. Read More: https://lnkd.in/g85nxCpD

Discover game-changing treatment for obesity and type 2 Diabetes, paving the way for a healthier future! Eli Lilly has developed a new class of treatment that has proven to be highly effective in obese patients. With obesity projected to affect 1 billion people by 2030, this breakthrough is a game-changer. The FDA has approved Mounjaro® (tirzepatide), a novel glucose-dependent insulinotropic and glucagon-like peptide 1 receptor agonist, for the treatment of T2D, as well as in obese patients. This clinical trial was made possible through preclinical data collected with the #PhenoMaster – metabolic phenotyping system for mice by TSE Systems. If you're interested in exploring your research needs, please visit: https://lnkd.in/dZfihSwc. Read more: https://lnkd.in/d2pi3XZB #Obesity #TSESystems #Innovation #GlobalHealth #Metabolism

Researchers from Rockefeller University have made a groundbreaking discovery in the study of cell receptors, published in Science Advances. They've developed a novel technique to map interactions between 215 G protein-coupled receptors (GPCRs) and receptor activity-modifying proteins (RAMPs), revealing complex partnerships that significantly expand our understanding of their biological roles. This advanced mapping technique highlights the nuanced ways in which GPCRs, which are targeted by about a third of all FDA-approved drugs, interact with RAMPs to modify cellular signals. This insight is pivotal for developing more precise medications that can specifically target these receptor complexes, potentially revolutionizing treatments for a wide range of diseases, from cardiovascular disorders to allergies. #ScienceAdvances #DrugDevelopment #GPCRs #PrecisionMedicine Read more: https://lnkd.in/eXceTsHe

How could mitochondrial targeting help develop new therapies against immune and inflammatory diseases? Read this new review published in Frontiers in Drug Discovery written by Prof Luke O'Neill and Yukun Min (Trinity College Dublin) to find out: https://lnkd.in/etHaveJv #immunometabolism #mitochondria #mtDNA #mtRNA #openaccess #drugdiscovery #antiinflammatory #therapeutics

Prof. Piotr Trzonkowski, Chief Executive Officer at PolTREG explained the great potential of cell therapies and PolTREG’s unique achievements in treating autoimmune diseases, in an interview with Polish business newspaper Gazeta Giełdy i Inwestorów „Parkiet”. Some highlights from the interview: ✅ PolTREG just announced the results from a long-term study in treating type 1 diabetes, demonstrating safety and efficacy of up to 12 years after PolTREG began administering its therapies. No other company in the world has such long-term results. The study is due to be published at a conference in September. ✅PolTREG has the most advanced pipeline of Treg candidate therapies. It is the only company developing all modalities of Treg therapies for auto-immune disease: from polyclonal T-cells to several types of engineered T-cells, autologous and allogeneic.   ✅ PolTREG has a unique ability to manufacture cell therapies in its proprietary GMP-certified facility, where it can produce 1,500 therapies per year, which can be shipped across Europe within 24 hours. Watch the full interview (in Polish): https://lnkd.in/dqRy-utV #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes #type1diabetes

Addition of HSV-1 or SARS-CoV-2 to human cerebrospinal fluid (CSF) leads to the amyloid aggregation of several proteins known to be involved in neurodegenerative diseases, including APLP1 (amyloid beta precursor like protein 1), ApoE, clusterin, α2-macroglobulin, PGK-1, ceruloplasmin, nucleolin, 14-3-3, transthyretin and vitronectin. Amyloid formation is dependent on viral surface catalysis via direct physicochemical mechanism of heterogenous nucleation (HEN) and not its ability to replicate, suggesting that some viruses known to replicate in the central nervous system may act as physical catalysts of amyloid nucleation. The researchers highlight the findings as a potential mechanism to explain the association between persistent and latent/reactivating brain infections and certain neurodegenerative diseases. #COVID19 #HSV1 #herpesvirus #dementia #alzheimer #longcovid #health #globalhealth #publichealth #medicine #biotechnology #pharmaceuticals FDA #WHO #CDC #ECDC https://sco.lt/5iXxWS

As of 31 May 2023, 16 participants were enrolled across 5 dose cohorts. Twelve of the 16 participants completed the dose-optimization study and enrolled in the extension study. A total of 346 intravenous doses of mRNA-3927 were administered over a total of 15.69 person-years of treatment. No dose-limiting toxicities occurred. Treatment-emergent adverse events were reported in 15 out of the 16 (93.8%) participants. Preliminary analysis suggests an increase in the exposure to mRNA-3927 with dose escalation, and a 70% reduction in the risk of metabolic decompensation events among 8 participants who reported them in the 12-month pretreatment period. https://lnkd.in/gTfbTFzU

Milk-derived exosomes --- Oral administration is an ideal method for treating inflammatory bowel disease by delivering drugs directly to the small intestine and colon. In this recently published study, scientists developed a new oral siRNA delivery system using milk-derived exosomes to protect nucleic acids in harsh environments. These milk exosomes showed exceptional stability compared to exosomes from cell culture, making them effective siRNA carriers. Due to unique lipids with high bioavailability, orally administered milk-derived exosomes reach colonic tissues, reducing TNF-α expression and relieving colitis symptoms in a murine model. Using milk-derived exosomes for TNF-α siRNA delivery could be a promising approach to treating inflammatory bowel disease. Read the publication here: https://lnkd.in/epCv4aux #research #lipid #lipidomics #LipidMetabolism #lipotype #lipidome #exosome #InflammatoryBowelDisease #IBS #siRNA

In the final installment of the “Scrip Asks” article series covering important advances in #biopharma, Giacomo Chiesi, Head of Chiesi Global Rare Diseases, shares insights on key developments affecting #RareDisease research and drug development. Read the full article here: https://lnkd.in/d-sTmHhS Citeline Commercial #RareDiseases #ChiesiGlobalRareDiseases